Atrys Health (ATRY) Q2 2025 earnings summary

Executive summary

• Revenue for 1H25 reached €115.8M, up 7.8% year-over-year, driven by strong growth in Oncology (+16.9%) and Diagnostics (+9.8%).

• Net loss attributable to the parent was €9.3M, an improvement from €16.5M in the prior year.

• All business segments showed revenue growth, with Diagnostics, Oncology, and Prevention contributing significantly.

• Notable expansion in Medical Oncology in Spain (+21%) and Mexico (+36%), with new centers opened and more planned.

• Strategic review underway to focus on high-growth areas, consider divestment of non-core assets, and reduce debt.

Financial highlights

• Gross margin was €73.9M (63.7% of revenue), down from 67.2% in 1H24 due to mix shift and higher costs in Medical Oncology.

• Adjusted EBITDA fell 13.3% to €21.9M, mainly due to lower R&D grant income; excluding this, EBITDA would have grown 3.4%.

• Consolidated operating income was €1.1M, compared to a €5.3M operating loss in the previous year.

• Net consolidated result improved to a loss of €9.4M from €16.5M in 1H24.

• Cash and cash equivalents at period end were €13.6M, down from €20.4M at the start of the year.

Outlook and guidance

• Focus on organic growth in strategic geographies and business lines.

• Plans to accelerate growth in high-potential areas and maximize shareholder value through asset divestments and debt reduction.

• Expectation to recover part of the margin decline in Medical Oncology Spain in Q4 during contract renegotiations.

• Management expects continued revenue growth across all segments, with a focus on operational efficiency.